Oncolytics Biotech Inc

Financials

Activos totales —————7.58 M Total de pasivos 6.73 M6.73 M6.73 M6.73 M6.73 M11.38 M Capital total —————-3.8 M Total de pasivos y patrimonio neto 6.73 M6.73 M6.73 M6.73 M6.73 M7.58 M Deuda total —————— Deuda neta ——————

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

ONCY

Financials

Oncolytics Biotech Inc

Noticias

H.C. Wainwright reitera calificación de compra para Oncolytics Biotech

Oncolytics programa reunión con la FDA sobre vía de desarrollo de fármaco para cáncer anal

Oncolytics Biotech completa primer paso de redomiciliación a Columbia Británica

Oncolytics inicia estudio fase 2 de cáncer colorrectal REO 033

Oncolytics launches phase 2 colorectal cancer study REO 033

Oncolytics cerrará estudio GOBLET y se enfocará en registro en EE.UU.

Oncolytics to wind down GOBLET study, focus on U.S. registration

Las acciones de Oncolytics Biotech se disparan tras la designación Fast Track de la FDA

Acciones de Oncolytics Biotech se disparan tras designación Fast Track de FDA

Oncolytics Biotech stock soars after FDA grants Fast Track Designation

Pelareorep-atezolizumab muestra resultados prometedores en cáncer anal

Pelareorep-atezolizumab shows promising results in anal cancer